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Background: The emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has intensified
efforts to discover novel drugs for tuberculosis (TB) treatment. Targeting the persistent state of Mtb, a condition in
which Mtb is resistant to conventional drug therapies, is of particular interest.
Methods: This study is focused on propargyl acetate derivatives. Eight molecules were designed based on
propargyl alcohols and different acid anhydrides.
Results: All the synthesized compounds and commercially available ones were evaluated for anti-tuberculosis
activity.
Conclusions: Inhibitors against Mtb have been identified and characterized for further development into potential
novel anti-tubercular drugs.
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Tuberculosis (TB) is a deadly infectious disease and is
the leading cause of death worldwide, killing around 2
million people annually, primarily in developing coun-
tries. The World Health Organization (WHO) estimates
that over one third of the world’s population is infected
with TB with approximately 8 million new cases of infec-
tion diagnosed every year [1-3]. After human immuno-
deficiency virus (HIV)/AIDS, TB is the second most
common cause of death due to an infectious disease,
and current trends suggest that TB will still be among
the 10 leading causes of global disease burden in the
year 2020 [4]. TB incidence is also on the rise because of
the correspondingly high HIV infection rates. These two
diseases progress at faster rates in co-infected indivi-
duals. The immune systems have been compromised by
HIV/AIDS, so individuals fall victims to TB which takes
opportunity of their weakened immune systems. There
is a great interest in the scientific field to come up with
a new drug(s) to combat TB. Tuberculosis is an airborne* Correspondence: ssardari@hotmail.com
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reproduction in any medium, provided the orinfectious disease caused by mycobacteria, mainly Mycobac-
terium tuberculosis (Mtb) [5]. The success of mycobacteria
in producing disease relies entirely on its ability to utilize
macrophages for its replication and more importantly, the
maintenance of viability of host macrophages that sustain
mycobacteria.
In the present scenario, due to the emergence of
multi-drug resistant tuberculosis (MDR-TB) and associ-
ation between HIV and TB, Directly Observed Treat-
ment Short course (DOTS) is becoming rapidly
ineffective in controlling tuberculosis. Recent reports in-
dicate that, areas where there is a high incidence of
MDR-TB, DOTS is failing to control the disease [6]. In
such circumstances, the second line drugs are prescribed
in combination with DOTS. However, this combination
of drugs is very expensive, are less effective and thus has
to be administered for a longer duration (e.g. p-amino
salicylic acid), has significant side effects (e.g., cycloser-
ine) and some are unavailable in many developing coun-
tries (e.g. fluoroquinolones).
Hence, it is clear that there is an urgent need to de-
velop novel anti-TB drugs with improved properties
such as enhanced activity against multidrug-resistance,
reduced toxicity, shortened duration of therapy, rapid
mycobactericidial mechanism of action, ability tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in the intracellular environment.
Alkynes or acetylenic compounds play an important
role as building blocks in many synthetic transforma-
tions, and in new materials. In addition acetylenic group
is common structural motifs found in various natural
products and also great interest in medicinal chemistry
and the pharmaceutical industry [7]. It moreover func-
tions as a key pharmacophoric unit in acetylenic antibio-
tics [8] and its presence in anticancer [9] and anti-
tubercular [10] agents is noteworthy.
Due to above-mentioned reasons and as a part of our
ongoing research program on the synthetic methods in
organic compounds [11,12], and also our drug discovery
program [13,14], here a series of new acetylenic com-
pounds (propargyl acetate derivatives ) were synthesized
and evaluated for anti-tubercular activity.
Methods
General
Infrared spectra were determined with a Perkin-Elmer
843 spectrometer (USA). Proton nuclear magnetic res-
onance (1H NMR) spectra and carbon nuclear magnetic
resonance (13C NMR) spectra were determined on a
Bruker Avance DRX 500 MHz spectrometer (Germany)
and chemical shifts are reported as δ (ppm) in CDCl3
solution (0.05% v/v TMS). GC/MS spectra were obtained
using Agilent 7000 Triple Quad (USA). (EI at 70 eV).
The chemicals used in this work were purchased from
Merck (Germany), Fluka (Germany) and Sigma-Aldrich
(USA) Chemical Companies.
In vitro evaluation of anti-mycobacterial activity
In vitro anti-mycobacterial activity evaluations of the
compounds were done by the broth microtiter dilution
method) against BCG (1173P2) and ethambutol were
used as standard controls.
The test compounds were initially dissolved in DMSO
to give a concentration of 1 or 2 mg/L. All wells of
micro plates received 100 μL of freshly prepared Middle
broke 7H9 medium (Himedia, India), except first col-
umn. 200 μL of distilled water was added to the first col-
umn of 96 well plates to minimize evaporation of the
medium in the test wells during incubation. Then 100
μL of test compounds with desired concentrations (1000
or 2000 μL) were added to the wells of the first row
(each concentration was assayed in duplicate) and serial
dilution was made from the first row to the last. Micro-
bial suspension of BCG (1173P2) (100 μL), which had
been prepared with standard concentration of 0.5 Mcfar-
land and diluted with 1:10 proportion by the distilled
water, was added to all test wells. Plates were then sealed
and incubated for 4 days at 37°C. After that 12 μl Tween
80 10% and 20 μl Alamar blue 0.01% (Himedia, India)were added to each test well. The results were assessed
after 24 and 48 hours. A blue color was interpreted as
no bacterial growth, and color change to pink was
scored as bacterial growth. Wells with a well-defined
pink color were scored as positive for growth. The MIC
(minimum inhibitory concentration) was defined as the
lowest drug concentration, which prevented a color
change from blue to pink. Ethambutol (Irandaru, Tehran)
were used as positive control and DMSO as negative
control [15].
General procedure for the preparation of propargyl
acetate derivatives 3a-h
To a magnetically stirred solution of anhydride (1.2 mmol)
was added 3 drops of concentrated sulfuric acid and mix
thoroughly holding the large test tube containing the
acetic anhydride in cold water. Then, the alcohol (1 mmol)
was added to it in several increments and the reaction
mixture stirred at room temperature. After, the reaction
mixture was placed in hot water at about 70°C to complete
the reaction; the progress of the reaction was monitored by
TLC (ethyl acetate/n-hexane, 2:1). The purification of prod-
uct was done according to the literature [16].
Prop-2-ynyl acetate (3a): Yellow liquid (yield 65%). 1H
NMR (500 MHz, CDCl3): δH (ppm) 2.07 (3H, s, CH3),
2.46 (1H, t, 4JHH = 2.5 Hz, ≡CH), 4.64 (1H,d,
4JHH =
2.5 Hz, OCH2).
13C NMR (125 MHz, CDCl3): δC (ppm)
30.7 (CH3), 51.9 (OCH2), 74.8 and 77.6 (two acetylenic
carbons), 170.1 (C =O). IR (KBr) (νmax,cm
-1): 3468, 3296,
2948, 2125, 1733. GC EI-MS, m/z: 99 (M+· + H+, 3%).
But-3-yn-2-yl acetate (3b): Yellow liquid (yield 70%).
1H NMR (500 MHz, CDCl3): δH (ppm) 1.49 (3H, d,
CH3), 2.06 (3H, s, CH3), 2.44 (1H, s, ≡CH), 5.39-5.43
(1H, m, OCH). 13C NMR (125 MHz, CDCl3): δC (ppm)
21.00 (CH3), 21.2 (CH3), 60.0 and 82.1 (two acetylenic
carbons), 72.8 (OCH), 169.8 (C =O). IR (KBr) (νmax,cm
-1):
3480, 3308, 2999, 2131, 1739. GC EI-MS, m/z: 113
(M+· + H+, 10%).
3-Methylpent-1-yn-3-yl acetate (3c): Yellow liquid
(yield 63%). 1H NMR (500 MHz, CDCl3): δH (ppm) 1.02
(3H, t, 3JHH = 7.4 Hz, CH3), 1.06 (3H, s, CH3), 1.84
(2H, q, 3JHH = 7.4 Hz, CH2), 2.03 (3H, s, CH3), 2.54
(1H, s, ≡CH). IR (KBr) (νmax,cm
-1): 3306, 2967, 2867,
2135, 1716. GC EI-MS, m/z: 140 (M+·, 10%).
Oct-1-yn-3-yl acetate (3d): Yellow liquid (yield 60%). 1H
NMR (500 MHz, CDCl3): δH (ppm) 0.88 (3H, t,
3JHH =
7.0 Hz, CH3), 1.30 (2H, m, CH2), 1.43 (2H, m, CH2), 1.75
(2H, m, CH2), 2.07 (3H, s, CH3), 2.44 (1H, d,
4JHH =
2.5 Hz, ≡CH), 5.32 (H, t of d, 3JHH = 5.0 Hz,
4JHH = 2.5 Hz,
OCH). 13C NMR (125 MHz, CDCl3): δC (ppm) 13.9
(CH3), 20.9 (CH3), 22.2 (CH2), 24.4 (CH2), 31.0 (CH2),
34.4 (CH2), 63.7 and 77.2 (two acetylenic carbons), 82.0
(OCH2), 169.9 (C =O). IR (KBr) (νmax,cm
-1): 3300, 2964,
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Scheme 1 Synthesis of propargyl acetate derivatives.
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NMR (500 MHz, CDCl3): δH (ppm) 2.01 (1H, t,
4JHH =
3.0 Hz, ≡CH), 2.10 (3H, s, CH3), 2.54 (2H, t of d,
3JHH =
6.5 Hz, 4JHH = 3.0 Hz, CH2), 4.19 (2H, t,
3JHH = 7.0 Hz,
OCH2).
13C NMR (125 MHz, CDCl3): δC (ppm) 18.8
(CH3), 20.7 (CH2), 61.7 and 70.1 (two acetylenic car-
bons), 80.0 (OCH2), 170.8 (C =O). IR (KBr) (νmax,cm
-1):
3315, 3028, 2900, 2290, 1738. GC EI-MS, m/z: 113
(M+· + H+, 10%).
Prop-2-ynyl heptanoate (3f ): Yellow liquid (yield 78%).
1H NMR (500 MHz, CDCl3): δH (ppm) 1.31 (3H, t,
3JHH = 7.5 Hz, CH3), 1.63 (8H, m, 4CH2), 2.33 (2H, t,
3JHH = 8.0 Hz, CH2), 4.45 (1H, t,
4JHH = 2.0 Hz, ≡CH),
4.65 (2H, d, 4JHH = 2.0 Hz, OCH2).
13C NMR
(125 MHz, CDCl3): δC (ppm) 13.8 (CH3), 22.2, 24.4,
31.1, 33.8, (4CH2), 51.6 and 74.6, (two acetylenic carbons),
77.7 (OCH2), 172.9 (C =O). IR (KBr) (νmax,cm
-1): 3291,
2932, 2865, 2128, 1738. GC EI-MS, m/z: 168 (M+·, 10%).
Oct-1-yn-3-yl heptanoate (3g): liquid (yield 55%). 1H
NMR (500 MHz, CDCl3): δH (ppm) 0.89 (6H, m, 2CH3),
1.31 (4H, m), 1.43 (4H, m), 1.63 (4H, m), 1.75 (4H, m),
2.37 (2H, m), 2.42 (1H, d, 4JHH = 2.5 Hz, ≡CH), 5.34 (1H,
t of d, 3JHH = 6.5 Hz,
4JHH = 2.0 Hz, OCH). IR (KBr)
(νmax,cm
-1): 3310, 2963, 2872, 2127, 1736. GC EI-MS,
m/z: 239 (M+·, 10%).
But-3-ynyl heptanoate (3h): Yellow liquid (yield 70%).
1H NMR (500 MHz, CDCl3): δH (ppm) 0.87 (3H, t,
3JHH = 7.0 Hz, CH3), 1.30 (4H, m, CH2), 1.61 (2H, m,
CH2), 1.98 (1H, t,
4JHH = 2.5 Hz, ≡CH), 2.32 (2H, m,
CH2), 2.50 (2H, t of d,
3JHH = 7.0 Hz,
4JHH = 3.0 Hz,
CH2), 4.16 (2H, t,
3JHH = 7.0 Hz, OCH2 ).
13C NMR
(125 MHz, CDCl3): δC (ppm) 13.9 (CH3), 19.0, 22.3,
24.4, 31.2, 34.14 (5CH2), 61.9 and 69.9 (two acetylenic car-
bons), 80.1(OCH2), 173.6 (C =O). IR (KBr) (νmax,cm
-1): 3304,
2961, 2868, 2126, 1735. GC EI-MS, m/z: 182 (M+·, 5%).
Results and discussion
Esterification of alcohols using acid anhydrides in the
presence of acid or base catalyst has been known and
extensively used by organic chemists for nearly 100 years
[17]. Hydroxyl compounds are often converted to acet-
ate derivatives for protection or characterization of the
structure. For this purpose, acetic anhydride is com-
monly employed with an acid or base catalyst, such as
zinc chloride, concentrated sulphuric acid, anhydrous
sodium [18] acetate or, most often, pyridine [19].
In the present work, propargyl acetate derivatives 3a-h
were prepared by acylation of propargyl alcohols 1 with
acid anhydrides 2 in H2SO4 (Scheme 1) [20].
The reactions are straightforward and as indicated in
Scheme 1, treatment of various propagyl alcohols 1 with
acid anhydrides 2 in H2SO4 led to products 3a-h. To ex-
plore the scope and variety of biological activity for pro-
ducts of this reaction, we have examined variousprimary, secondary and tertiary propagyl alcohols in the
presence of aliphatic and aromatic acid anhydrides in
H2SO4 at room temperature. As indicated Figure 1, the
reaction proceeds efficiently and led to highly functiona-
lized propargyl acetate derivatives 3a–h in good yields.
The structures of compounds 3a–h were deduced from
their 1H NMR and 13C NMR spectroscopic data. For ex-
ample, the 1H NMR spectrum of 3a exhibited a singlet at
2.07 (CH3), a triplet at 2.46 (
4JHH = 2.5Hz) for acetylenic
hydrogen (≡CH) and a doublet at 4.64 (4JHH = 2.5 Hz,
OCH2). The
1H decoupled 13C NMR spectrum of 3a
showed 5 distinct resonances, and partial assignment of
these resonances is given in experimental section.
All the synthesized compounds were evaluated for
anti-tubercular activity and the results are summarized
in Figure 1.
Compounds 3a-h have almost the same activity except
3 g that is slightly stronger; it shows that the changing
of R1, R2 and R3 is not important in these compounds.
Therefore, we did not synthesis more derivatives from
these compounds. In continuation of the work, we
investigated different groups of organic compounds that
all of these compounds containing acetylenic group in
difference situation, such as alcohols (4–10), acetylenic
compounds (11–16), esters (17–20), acids (21), and
anhydrides (22–25) (without acetylenic group). In these
compounds (4–25), the nature and location of men-
tioned functional group can affect the anti-bacterial ac-
tivity of acetylenic compounds. As can be seen from
Figure 2, among these acetylenic compounds (11,12,15,
16) and esters (17–20), have almost similar effect and
more bioactivity than others. It seems that replacement
of alkyne hydrogen with an alkyl or aryl group in case of
compounds 12 and 16 and a balanced hydrophobicity
playing with special features, in case of compounds 11
and 15 have beneficial effect on the bioactivity. However,
it is necessary to examine the possible mechanism of ac-
tion in detail to clear the reason for the variations of
activity.
It is interesting to note that comparison of compounds
3a-h in Figure 1 and 17–20 in Figure 2 which are ester
shows that 17–20 more active than 3a-h (3.87 vs 125).
This can be because of difference in structure of two
classes of esters. The main structural difference between















3a 3b 3c 3d 3e
3f 3g 3h
Entry R1 R2 R3
MIC (µg/ml)
24/48 (hours)
3a H H Methyl 125/125
3b H Methyl Methyl 125/125
3c Methyl Ethyl Methyl 125/125
3d H Pentyl Methyl 125/125
3e H H Methyl 125/125
3f H H Hexyl 125/125
3g H Pentyl Hexyl 62.50/62.50
3h H H Hexyl 125/125
Ethambutol 0.75/0.75
DMSO 6.5/6.5% (v/v)
Figure 1 Synthesized propargyl acetate derivatives and their MIC.
Figure 2 Commercially available substrates and their MIC (minimal inhibition concentration).
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double bond with the triple bond and the resulting di-
pole moment is a feature that can explain this difference.
The same effect can play a role for the better activity of
compounds 15 and 16.
Conclusions
In conclusion, the synthesized new class of propargyl
acetate derivatives and commercially available com-
pounds were evaluated for anti-tuberculosis activity.
Among them, 11, 12, 15, 17 and 18 exhibited promising
activity against of M. bovis.
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